Who / What
The term "Fast track" refers to a designation and regulatory program by the United States Food and Drug Administration (FDA). It's not an entity itself but rather describes a special review pathway applied to certain types of investigational drug applications. This system is designed specifically for drugs intended to treat serious or life-threatening conditions.
---
Background & History
The Fast track designation emerged as part of a broader effort by the FDA in the mid-to-late 1990s to streamline and expedite the development review process, particularly for products addressing public health needs. It was formally established through guidance issued around **December 1992** under the leadership of then-FDA Commissioner Dr. David Kessler. Significant updates occurred after **March 2003**, incorporating requirements from the Food and Drug Administration Modernization Act (FDAMA).
---
Why Notable
Fast track is a notable mechanism because it aims to accelerate patient access to promising new therapies, especially for conditions lacking adequate treatments or those that are life-threatening. It facilitates earlier dialogue between drug developers and FDA reviewers regarding development plans, designates one qualified reviewer responsible for the application, and allows co-primary review team members. Its impact lies in potentially reducing development timelines without compromising regulatory standards.
---
In the News
Current relevance stems from its ongoing use during public health emergencies like the COVID-19 pandemic to expedite vaccines and treatments. It also plays a vital role in advancing oncology drugs (cancer treatments) where rapid approval can significantly improve patient outcomes. The program remains frequently discussed as part of FDA's efforts to encourage innovation for unmet medical needs, particularly complex ones.
---
Key Facts
---
